| Previous Close | 55.5 |
| Open | 55.66 |
| Day High | 58.17 |
| Day Low | 55.44 |
| 52-Week High | 65 |
| 52-Week Low | 29.08 |
| Volume | 717,700 |
| Average Volume | 1.61M |
| Market Cap | 8.38B |
| PE | -8.44 |
| EPS | -6.88 |
| Moving Average 50 Days | 52.39 |
| Moving Average 200 Days | 51.44 |
| Change | 2.54 |
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
GlobeNewswire Inc.
Feb 11, 2026 9:05 PM GMT
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 OPUS-1, VAX-31 Adult Phase 3 Noninferiority Trial, Continues to
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
GlobeNewswire Inc.
Feb 10, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth quarter and full year 2025 and provide a business
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
GlobeNewswire Inc.
Feb 05, 2026 9:05 PM GMT
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech